Literature DB >> 23129211

Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.

Shringi Sharma1, Ewa C S Ellis, Roberto Gramignoli, Kenneth Dorko, Veysel Tahan, Marc Hansel, Donald R Mattison, Steve N Caritis, Ronald N Hines, Raman Venkataramanan, Stephen C Strom.   

Abstract

Little information is available in the literature regarding the expression and activity of transporters in fetal human liver or cultured cells. A synthetic progesterone structural analog, 17α-hydroxyprogesterone caproate (17-OHPC), is used in the prevention of spontaneous abortion in women with a history of recurrent miscarriage (habitual abortion). 17-OHPC has been reported to traverse the placental barrier and gain access to fetal circulation. In this study, the role of transporters in the disposition of 17-OHPC in fetal and adult human hepatocytes was examined. Progesterone metabolites have been reported to induce trans-inhibition of bile acid transporter, ABCB11. Thus, we investigated the effect of 17-OHPC or its metabolites on [(3)H]taurocholic acid transport in sandwich-cultured human fetal and adult hepatocytes. 17-OHPC was taken up rapidly into the cells and transported out partially by an active efflux process that was significantly inhibited by cold temperature, cyclosporine, verapamil, and rifampin. The active efflux mechanism was observed in both adult and fetal hepatocyte cultures. 17-OHPC produced a concentration-dependent inhibition of taurocholate efflux into canaliculi in sandwich-cultured adult and fetal human hepatocytes. However, given the high concentrations required to cause inhibition of these transport processes, no adverse effects would be anticipated from therapeutic levels of 17-OHPC. We also evaluated the expression of various hepatic transporters (ABCB1, ABCB4, SLCO1B1, SLCO1B3, SLCO2B1, ABCB11, SLC10A1, ABCC2, ABCC3, ABCC4, and ABCG2) in fetal and adult hepatocytes. With the exception of ABCB4, all transporters examined were expressed, albeit at lower mRNA levels in fetal hepatocytes compared with adults.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23129211      PMCID: PMC3558857          DOI: 10.1124/dmd.112.044891

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  34 in total

1.  Intrahepatic cholestasis of pregnancy: what's new.

Authors:  G Kroumpouzos
Journal:  J Eur Acad Dermatol Venereol       Date:  2002-07       Impact factor: 6.166

2.  Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2.

Authors:  Y Cui; J König; D Keppler
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

3.  The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.

Authors:  K Fattinger; C Funk; M Pantze; C Weber; J Reichen; B Stieger; P J Meier
Journal:  Clin Pharmacol Ther       Date:  2001-04       Impact factor: 6.875

4.  Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression.

Authors:  M G Ladona; M L Gonzalez; A Rane; R M Peter; R de la Torre
Journal:  Life Sci       Date:  2000-12-15       Impact factor: 5.037

5.  Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.

Authors:  C Funk; C Ponelle; G Scheuermann; M Pantze
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

6.  Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.

Authors:  Jian Zong; Gary M Pollack
Journal:  J Pharmacol Exp Ther       Date:  2003-04-29       Impact factor: 4.030

7.  Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats.

Authors:  Vsevolod E Kostrubsky; Stephen C Strom; Janean Hanson; Ellen Urda; Kelly Rose; James Burliegh; Philip Zocharski; Hongbo Cai; Jacqueline F Sinclair; Jasminder Sahi
Journal:  Toxicol Sci       Date:  2003-08-27       Impact factor: 4.849

8.  Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.

Authors:  Stephan R Vavricka; Jessica Van Montfoort; Huy Riem Ha; Peter J Meier; Karin Fattinger
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

9.  Prenatal and neonatal drug metabolism in man.

Authors:  A Rane; G Tomson
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

10.  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

Authors:  Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

View more
  12 in total

1.  Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny.

Authors:  Nicholas L Giebel; Jeffrey D Shadley; D Gail McCarver; Kenneth Dorko; Roberto Gramignoli; Stephen C Strom; Ke Yan; Pippa M Simpson; Ronald N Hines
Journal:  Drug Metab Dispos       Date:  2016-02-26       Impact factor: 3.922

Review 2.  Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

Authors:  Kyunghee Yang; Cen Guo; Jeffrey L Woodhead; Robert L St Claire; Paul B Watkins; Scott Q Siler; Brett A Howell; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

3.  Correlation between Conjugated Bisphenol A Concentrations and Efflux Transporter Expression in Human Fetal Livers.

Authors:  Jamie E Moscovitz; Muna S Nahar; Stuart L Shalat; Angela L Slitt; Dana C Dolinoy; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2016-02-05       Impact factor: 3.922

Review 4.  Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.

Authors:  K L R Brouwer; L M Aleksunes; B Brandys; G P Giacoia; G Knipp; V Lukacova; B Meibohm; S K Nigam; M Rieder; S N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2015-09       Impact factor: 6.875

5.  Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

Authors:  Nina Isoherranen; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2013-02       Impact factor: 3.922

6.  Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters.

Authors:  Miriam G Mooij; Ute I Schwarz; Barbara A E de Koning; J Steven Leeder; Roger Gaedigk; Janneke N Samsom; Edwin Spaans; Johannes B van Goudoever; Dick Tibboel; Richard B Kim; Saskia N de Wildt
Journal:  Drug Metab Dispos       Date:  2014-05-14       Impact factor: 3.922

Review 7.  Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.

Authors:  Kit Wun Kathy Cheung; Bianca D van Groen; Gilbert J Burckart; Lei Zhang; Saskia N de Wildt; Shiew-Mei Huang
Journal:  J Clin Pharmacol       Date:  2019-09       Impact factor: 3.126

8.  Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth.

Authors:  Alex C Vidaeff; Michael A Belfort
Journal:  Patient Prefer Adherence       Date:  2013-07-11       Impact factor: 2.711

Review 9.  Establishment of metabolism and transport pathways in the rodent and human fetal liver.

Authors:  Jamie E Moscovitz; Lauren M Aleksunes
Journal:  Int J Mol Sci       Date:  2013-12-06       Impact factor: 5.923

Review 10.  Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics.

Authors:  Miriam G Mooij; Anne T Nies; Catherijne A J Knibbe; Elke Schaeffeler; Dick Tibboel; Matthias Schwab; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.